Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of subcutaneous human immunoglobulin in primary immunodeficiency
CTR20264010Phase 3Active
- Sponsor
- Weiguang Biological
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Gamimune-N in Immunogenetic disorder, Primary antibody deficiency (PAD), X-linked agammaglobulinemia (XLA), common variable immunodeficiency (CVID), sponsored by Weiguang Biological. Started Oct 2026; status: active.
02
Drugs
Gamimune-N
03
Conditions
Immunogenetic disorderPrimary antibody deficiency (PAD)X-linked agammaglobulinemia (XLA)common variable immunodeficiency (CVID)
Beyond the preview
Go deeper on CTR20264010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264010.